0.1802 -0.014 (-6.97%) | 12-21 15:59 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.39 | 1-year : | 0.53 |
Resists | First : | 0.34 | Second : | 0.46 |
Pivot price | 0.17 | |||
Supports | First : | 0.14 | Second : | 0.12 |
MAs | MA(5) : | 0.17 | MA(20) : | 0.18 |
MA(100) : | 0.28 | MA(250) : | 0.71 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 17.9 | D(3) : | 12.9 |
RSI | RSI(14): 45.5 | |||
52-week | High : | 1.58 | Low : | 0.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BWV ] has closed above bottom band by 37.1%. Bollinger Bands are 59.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.17 - 0.17 | 0.17 - 0.17 |
Low: | 0.16 - 0.16 | 0.16 - 0.16 |
Close: | 0.17 - 0.17 | 0.17 - 0.17 |
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.
Mon, 18 Dec 2023
Proteomedix acquired by Blue Water Biotech to form Onconetix - The Pharma Letter
Tue, 17 Oct 2023
Blue Water Biotech names new CEO, CFO as company faces dual Nasdaq delisting notices - Cincinnati Business Courier - The Business Journals
Wed, 28 Jun 2023
Monkeypox Vaccine: Blue Water Biotech Touts Encouraging Preclinical Data From Monkeypox Vaccine Candidate - Yahoo Finance
Wed, 14 Jun 2023
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment ... - Yahoo Finance
Tue, 23 May 2023
Selling Blue Water Biotech Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for ... - Simply Wall St
Sun, 30 Apr 2023
UT Health Science Center San Antonio Launches Chlamydia Vaccine Study - Precision Vaccinations
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 19 (M) |
Shares Float | 14 (M) |
Held by Insiders | 17.6 (%) |
Held by Institutions | 23.4 (%) |
Shares Short | 23 (K) |
Shares Short P.Month | 60 (K) |
EPS | -1.09 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.56 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -30.3 % |
Return on Equity (ttm) | -101.7 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.75 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -12 (M) |
Levered Free Cash Flow | -18 (M) |
PE Ratio | -0.16 |
PEG Ratio | 0 |
Price to Book value | 0.29 |
Price to Sales | 0 |
Price to Cash Flow | -0.27 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |